InVivo Therapeutics (NVIV), Geisinger Health System to Conduct Clinical Studies for Treatment of Chronic Pain Associated with Peripheral Nerve Injury
InVivo Therapeutics Holdings Corp., developer of technologies to treat spinal cord injuries (SCI), and integrated health services organization Geisinger Health System today announced their collaborative research to conduct a preclinical study using InVivo’s injectable biocompatible hydrogel to treat chronic pain caused by peripheral nerve compression. InVivo said it plans to submit data from the study to the U.S. Food and Drug Administration (FDA) in 2012, marking the company’s first technology to treat degenerative neurologic conditions outside of the spinal cord. The company noted that approximately 3.2 million chronic pain injections are performed in the U.S. each year to treat patients…